Details

Autor(en) / Beteiligte

• Pagano, Gennaro
• Taylor, Kirsten I.
• Anzures-Cabrera, Judith
• Marchesi, Maddalena
• Simuni, Tanya
• Marek, Kenneth
• Postuma, Ronald B.
• Pavese, Nicola
• Stocchi, Fabrizio
• Azulay, Jean-Philippe
• Mollenhauer, Brit
• López-Manzanares, Lydia
• Russell, David S.
• Boyd, James T.
• Nicholas, Anthony P.
• Luquin, María R.
• Hauser, Robert A.
• Gasser, Thomas
• Poewe, Werner
• Ricci, Benedicte
• Boulay, Anne
• Vogt, Annamarie
• Boess, Frank G.
• Dukart, Juergen
• D’Urso, Giulia
• Finch, Rebecca
• Zanigni, Stefano
• Monnet, Annabelle
• Pross, Nathalie
• Hahn, Andrea
• Svoboda, Hanno
• Britschgi, Markus
• Lipsmeier, Florian
• Volkova-Volkmar, Ekaterina
• Lindemann, Michael
• Dziadek, Sebastian
• Holiga, Štefan
• Rukina, Daria
• Kustermann, Thomas
• Kerchner, Geoffrey A.
• Fontoura, Paulo
• Umbricht, Daniel
• Doody, Rachelle
• Nikolcheva, Tania
• Bonni, Azad

Titel

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

Ist Teil von

• The New England journal of medicine, 2022-08, Vol.387 (5), p.421-432

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2022

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• Prasinezumab is a monoclonal antibody to α-synuclein, a protein involved in the pathogenesis of Parkinson’s disease. In a placebo-controlled trial, prasinezumab did not slow the progression of disease over a period of 52 weeks.